Notice of Special Interest: Repurposing Existing Therapeutics to Address COVID-19
The North Carolina Translational and Clinical Sciences (NC TraCS) Institute wants you to be aware of a “Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)” released this week.
There are three Opportunities included in this notice.
- PAR-17-465 – “Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)” - due date: June 26, 2020.
- PAR-18-462 – “Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)” - First receipt date June 16, 2020.
- PAR-18-332 – “Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)” due date - June 5, 2020.
The stated purpose of the NOSI: “National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.”
